Current Report Filing (8-k)
March 21 2019 - 6:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
March 20, 2019
Frélii,
Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-107179
& 000-51210
|
|
980380519
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
2600
W. Executive Pkwy., Suite 500
Lehi,
UT 84043
(Address
of Principal Executive Offices)
(833)
437-3544
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01 Entry into a Material Definitive Agreement.
Frelii
Inc. has entered into a Memorandum of Understanding (MOU) with NewPath Health Care Solutions, Inc. of Ontario Canada, Mercator
Biologic, Inc. of Centerville, Utah and True DNA Story, LLC of Centerville Utah. The purpose of the MOU is to strategically explore
the full capabilities of each company to identify synergies and opportunities to leverage the unique skillsets of the collective.
The
intention of the MOU is to build a cooperative venture capable of leveraging the strengths of each company to enhance and further
the science of genetics, markets and potential clients’ quality of life. It also includes mutual cooperation in expanding
and improving on the established product portfolios and future plans.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Frélii, Inc.
|
|
|
|
Date:
March 20, 2019
|
By:
|
/s/
Ian Jenkins
|
|
Name:
|
Ian Jenkins
|
|
Title:
|
Chief Executive Officer
|
Frlii (CE) (USOTC:FRLI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Frlii (CE) (USOTC:FRLI)
Historical Stock Chart
From Sep 2023 to Sep 2024